Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2361]

Frontline treatment with single agent pembrolizumab followed by AVD...

Prof Pamela Allen - Emory University School of Medicine, Georgia, USA

Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma ( Prof Pamela Allen - Emory University School of Medicine, Georgia, USA )

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC

Dr Aditya Bardia - Mass General Cancer Center, Boston, USA

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer...

Dr Sara Hurvitz - University of California, Los Angeles, USA

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups ( Dr Sara Hurvitz - University of California, Los Angeles, USA )

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib +...

Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease ( Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA )

The RxPONDER trial and its impact on best clinical practice

Prof Christos Markopoulos and Prof Giuseppe Curigliano

The RxPONDER trial and its impact on best clinical practice ( Prof Christos Markopoulos and Prof Giuseppe Curigliano )

WHO and St. Jude Children’s research hospital to dramatically increase global...

Dr Andre Llbawi - World Health Organization (WHO) Global Childhood Cancer...

WHO and St. Jude Children’s research hospital to dramatically increase global access to childhood cancer medicine ( Dr Andre Llbawi - World Health Organization (WHO) Global Childhood Cancer Initiative )

The global platform for access to childhood cancer medicines

Dr James Downing - St. Jude Children’s Research Hospital, Memphis, USA

The global platform for access to childhood cancer medicines ( Dr James Downing - St. Jude Children’s Research Hospital, Memphis, USA )

Cancer medicine shortages for children around the world

Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis...

Cancer medicine shortages for children around the world ( Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis, USA )

Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first...

Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands

Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients ( Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )

Tisagenlecleucel shows no EFS improvement on standard of care in 2L for...

Dr Michael Bishop - University of Chicago, Chicago, USA

Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL ( Dr Michael Bishop - University of Chicago, Chicago, USA )

Latest in combination therapy for NDMM patients

Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA

Latest in combination therapy for NDMM patients ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )

ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high...

Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center...

ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer